Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma

Thrombosis and Haemostasis

Volumn 92, Issue 1, 2004, Pages 185-190

  Caine, Graham J ^a   Lip, Gregory Y H ^a   Stonelake, Paul S ^b   Ryan, Peter ^b   Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Interleukin 6; Platelets; Soluble P selectin

Indexed keywords

D DIMER; FIBRINOGEN; INTERLEUKIN 6; PADGEM PROTEIN; PROSTATE SPECIFIC ANTIGEN; THROMBOPLASTIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; BREAST BIOPSY; BREAST CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; THROMBOCYTE ACTIVATION;

EID: 3142623614     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-11-0679     Document Type: Article

References (47)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
3. Griffioen AW, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-68.
4. Benjamin L, Golijanin D, Itan A. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-65.
5. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/ vascular endothelial growth factor, microvascular hypermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
6. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15-35.
7. Verheul HM, Hoekman K, Luykx-Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90.
8. O'Byrne KJ, Dobbs N, Harris AL. Serum vascular endothelial growth factor load and interleukin-6 in cancer patients. Br J Cancer 2000; 82: 1895-6.
9. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956-64.
10. Bachelot T, Ray-Coquard I, Menetrier-Caux C, et al. Prognostic value of serum levels of interleukin-6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer. Br J Cancer 2003; 88: 1721-6.
11. Mohle R, Green D, Moore MA, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-8
12. Verheul HM, Jorna AS, Hoekman K, et al. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000; 96: 4216-21.
13. Blann AD, Lip GYH. Hypothesis: is soluble P selectin a new marker of platelet activation? Atherosclerosis 1997; 128: 135-8.
14. Blann AD, Gurney D, Wadley M, et al. Increased soluble P selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coag Fibrinolysis 2001; 12: 43-50.
15. Schadendorf D, Diehl S, Zuberbier T, et al. Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology 1996; 192: 89-93.
16. Haznedaroglou IC, Benekli M, Ozcebe O, et al. Serum L-selectin and P-selectin levels in lymphomas. Haematologica 2000; 30: 27-30
17. Roselli M, Mineo TC, Basili S, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost 2003; 89: 177-84.
18. Roselli M, Mineo TC, Martini F, et al. Serum concentrations of soluble selectins in patients with lung cancer. Int J Biol Markers 2002; 17: 56-62.
19. Salgado R, Benoy I, Weytjens R, et al. Arteriovenous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer 2002; 87: 1437-44.
20. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin-6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-6.
21. Bachelot T, Ray-Coquard I, Menetrier-Caux C, et al. Prognostic value of serum levels of interleukin-6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer. Br J Cancer 2003; 88: 1721-6.
22. Osterud B. Tissue factor: a complex biological role. Thromb Haemost 1997; 78: 755-8.
23. Bromberg ME, Sundaram R, Homer RJ, et al. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999; 82: 88-92.
24. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996; 167-8.
25. Kakkar AK, DeRuvo N, Chinswangwatanakul V, et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-5
26. Ueno T, Toi M, Koike M, et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164-70.
27. Makin AJ, Chung NA, Silverman SH, et al. Vascular endothelial growth factor and tissue factor in patients with established peripheral vascular disease: a link between angiogenesis and thrombogenesis? Clin Sci 2003; 104: 397-404.
28. Kamath S, Blann AD, Caine GJ, et al. Platelet P selectin in relation to plasma soluble P selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke 2002; 33: 1237-42.
29. Roldan V, Marin F, Blann AD, et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24: 1373-80.
30. Belgore FM, Lip GYH, Wadley M, et al. Plasma levels of vascular endothelial cell growth factor (VEGF) and its receptor (sFlt-1) in haematological cancers: a comparison with breast cancer. Am J Haematol 2001; 66: 59-61.
31. Altman D. Practical statistics for Medical Research, Chapman Hall, London, 1991.
32. Bachelot T, Ray-Coquard I, Menetrier-Caux C, et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of VEGF in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003; 88: 1721-6.
33. Ferrari L, Bajetta E, Martinetti A, et al. Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? Int J Oncol 2003; 22: 1081-9.
34. Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103: 642-6.
35. Benoy I, Salgado R, Colpaert C, et al. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002; 2: 311-5.
36. Pfitzenmaier J, Vessella. R, Higano CS, et al. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 2003; 97: 1211-6.
37. Akakura K, Suzuki H, Ueda T, et al. Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate 2003; 56: 106-9.
38. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-6.
39. Wise GJ, Marella VK, Talluri G, et al. Cytokine variations in patients with hormone treated prostate cancer. J Urol 2000; 164: 722-5.
40. Salgado R, Vermeulen PB, Benoy I, et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels in advanced cancer. Br J Cancer 1999; 80: 892-7.
41. Vermeulen PB, Salven P, Benoy I, et al. Blood platelets and serum VEGF in cancer patients. Br J Cancer 1999; 79: 370-3
42. Caine GJ, Stonelake PS, Lip GY, et al. The hypercoagulable state of malignancy; pathogenesis and current debate. Neoplasia 2002; 4: 465-73.
43. Lip GYH, Chin BSP, Blann AD. Cancer and the prothrombotic state. Lancet Oncology 2002; 3: 27-34.
44. Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72: 424-30.
45. Salgado R, Benoy I, Bogers J, et al. Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 2001; 4: 37-43.
46. Caine GJ, Lip GYH, Blann AD. Platelet-derived VEGF, flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Annals Med 2004: In press.
47. Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003: 24; 2166-79.